开瑞坦联合酮替芬治疗小儿咳嗽变异性哮喘50例临床观察

Clinical Observation on the Clinical Efficacy of Loratadine combined with Ketotifen in Treating 50 Children with Cough Variant Asthma

目的:观察开瑞坦联合酮替芬治疗小儿咳嗽变异性哮喘的临床疗效。方法:将50例咳嗽变异性哮喘患儿随机分为观察组和对照组,每组25例。对照组采用常规基础治疗,并加用酮替芬;观察组在对照组基础上加用开瑞坦进行治疗;两组治疗周期均为3个月,治疗结束后评定疗效。结果:观察组临床总有效率为92.00%,显著高于对照组的72.00%,差异有统计学意义(P<0.05);观察组患儿呼吸道感染次数、哮喘发作次数及咳嗽时间均显著少于对照组,差异亦均有统计学意义(P<0.05)。结论:开瑞坦联合酮替芬治疗小儿咳嗽变异性哮喘的临床疗效显著,值得在临床推广使用。

Objective： To observe the clinical efficacy of loratadine combined with ketotifen in treating children with cough variant asthma.Methods： 50 children with cough variant asthma were randomly divided into observation group and control group, 25 cases in each group.The children in the control group were treated with conventional basic treatment and ketotifen, and the children in the observation group were treated with loratadine on the basis of the treatment, and the course of the treatment was 3 months.The clinical efficacy were evaluated after the treatment.Results： The total effective rates in the observation group was 92.00%, which was significantly higher than that the control group（72.00%）（P〈0.05）, the number of respiratory infections, the number of asthma attacks and the coughing time were significantly less than those in the control group（P〈0.05）.Conclusion： Loratadine combined with ketotifen is effective in treating children with cough variant asthma, and worth being popularized in clinic.